Cargando…

Effects of Aprepitant on the Pharmacokinetics of Controlled-Release Oral Oxycodone in Cancer Patients

PURPOSE: Oxycodone is a µ-opioid receptor agonist widely used in the treatment of cancer pain. The predominant metabolic pathway of oxycodone is CYP3A4-mediated N-demethylation to noroxycodone, while a minor proportion undergoes 3-O-demethylation to oxymorphone by CYP2D6. The aim of this study was t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujiwara, Yutaka, Toyoda, Masanori, Chayahara, Naoko, Kiyota, Naomi, Shimada, Takanobu, Imamura, Yoshinori, Mukohara, Toru, Minami, Hironobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4133207/ https://www.ncbi.nlm.nih.gov/pubmed/25121773 http://dx.doi.org/10.1371/journal.pone.0104215

Ejemplares similares

Validity of new methods to evaluate renal function in cancer patients treated with cisplatin
por: Funakoshi, Yohei, et al.
Publicado: (2016)

Metabolomics Evaluation of Serum Markers for Cachexia and Their Intra-Day Variation in Patients with Advanced Pancreatic Cancer
por: Fujiwara, Yutaka, et al.
Publicado: (2014)

Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients
por: Fujiwara, Yutaka, et al.
Publicado: (2011)

Pharmacokinetic study of the oral fluorouracil antitumor agent S‐1 in patients with impaired renal function
por: Goto, Keiko, et al.
Publicado: (2019)

Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging
por: Nishimura, Meiko, et al.
Publicado: (2018)

The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer
por: Nishimura, Meiko, et al.
Publicado: (2016)

Mediastinal Germ Cell Tumor Exhibiting a Discrepancy between Tumor Markers and Imaging: A Case Study
por: Takenaka, Kei, et al.
Publicado: (2015)

Relationship between PDGFR expression and the response to pazopanib in intimal sarcoma of the pulmonary artery: A case report
por: Sai, Satoshi, et al.
Publicado: (2021)

Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
por: Suzuki, Chiaki, et al.
Publicado: (2021)

Left atrial extension of metastatic lung tumor via pulmonary vein: report on the first case of Ewing sarcoma
por: Funakoshi, Yohei, et al.
Publicado: (2010)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti‐Epidermal Growth Factor Receptor‐Induced Acne‐Like Rash: A Randomized Left‐Right Comparative Evaluation (APPEARANCE)
por: Chayahara, Naoko, et al.
Publicado: (2019)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

Device-related Mycobacterium mageritense Infection in a Patient Treated with Nivolumab for Metastatic Breast Cancer
por: Koyama, Taiji, et al.
Publicado: (2021)

Regorafenib-induced exacerbation of chronic immune thrombocytopenic purpura in remission: A case report
por: Kimbara, Shiro, et al.
Publicado: (2021)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Pooled post hoc analysis of population pharmacokinetics of oxycodone and acetaminophen following a single oral dose of biphasic immediate-release/extended-release oxycodone/acetaminophen tablets
por: Franke, Ryan M, et al.
Publicado: (2015)

Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits
por: Kura, Raghunandan Reddy, et al.
Publicado: (2018)

Characterization and Pharmacokinetic Study of Aprepitant Solid Dispersions with Soluplus(®)
por: Liu, Jinwen, et al.
Publicado: (2015)

Comparison of Pharmacokinetics of Aprepitant in Healthy Chinese and Caucasian Subjects
por: Yang, Meng-Jie, et al.
Publicado: (2020)

Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
por: Yamada, Kazuhiko, et al.
Publicado: (2010)

Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies
por: Minami, Hironobu, et al.
Publicado: (2020)

Secondary CIC-rearranged sarcoma responsive to chemotherapy regimens for Ewing sarcoma: A case report
por: Kimbara, Shiro, et al.
Publicado: (2021)

Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101)
por: Fujiwara, Yutaka, et al.
Publicado: (2015)

Relative Oral Bioavailability of an Abuse-Deterrent, Immediate-Release Formulation of Oxycodone, Oxycodone ARIR in a Randomized Study
por: Webster, Lynn R., et al.
Publicado: (2019)

Oxycodone Controlled Release in Cancer Pain Management
por: Biancofiore, Giuseppe
Publicado: (2006)

Oral Drug Delivery Systems Based on Ordered Mesoporous Silica Nanoparticles for Modulating the Release of Aprepitant
por: Christoforidou, Theodora, et al.
Publicado: (2021)

Treatment for Refractory Pruritus Using Oral Aprepitant
por: Huh, Joon Won, et al.
Publicado: (2016)

Ibuprofen gargle for chemo- or Chemoradiotherapy-induced Oral Mucositis: a feasibility study
por: Ioroi, Takeshi, et al.
Publicado: (2020)

Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer
por: Fujiwara, Satoe, et al.
Publicado: (2015)

Eribulin mesylate in patients with refractory cancers: a Phase I study
por: Mukohara, Toru, et al.
Publicado: (2011)

Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients
por: Villesen, Hanne H, et al.
Publicado: (2007)

Population Pharmacokinetics of Oxycodone and Metabolites in Patients with Cancer-Related Pain
por: Agema, Bram C., et al.
Publicado: (2021)

Oxycodone-Related Deaths: The Significance of Pharmacokinetic and Pharmacodynamic Drug Interactions
por: Jakobsson, Gerd, et al.
Publicado: (2022)

Abuse Potential Study of ALO-02 (Extended-Release Oxycodone Surrounding Sequestered Naltrexone) Compared with Immediate-Release Oxycodone Administered Orally to Nondependent Recreational Opioid Users
por: Setnik, Beatrice, et al.
Publicado: (2017)

Colorectal Transit and Volume During Treatment With Prolonged-release Oxycodone/Naloxone Versus Oxycodone Plus Macrogol 3350
por: Poulsen, Jakob L, et al.
Publicado: (2018)

Profile of extended-release oxycodone/acetaminophen for acute pain
por: Bekhit, Mary Hanna
Publicado: (2015)

Relapsing thrombotic microangiopathy and intravenous sustained-release oxycodone
por: Nataatmadja, Melissa, et al.
Publicado: (2016)

Urinary Pharmacokinetics of Immediate and Controlled Release Oxycodone and its Phase I and II Metabolites Using LC–MS-MS
por: Truver, Michael T, et al.
Publicado: (2021)

In response to Gudin et al. — Comparing the Effect of Tampering on the Oral Pharmacokinetic Profiles of Two Extended-Release Oxycodone Formulations with Abuse-Deterrent Properties
por: Crudele, Nancy T., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jjd0do45bkqnr4u70jmj9lubue